Vtrs fraud alert: jakubowitz law is investigating viatris inc. in connection with potential violations of federal securities laws

New york , may 5, 2023 /prnewswire/ -- jakubowitz law announces that an investigation into potential securities fraud allegations has commenced on behalf of shareholders of viatris inc. (nasdaqgs: vtrs) to be contacted by a member of our team, fill out the form: https://claimyourloss.com/securities/viatris-inc-class-action-loss-submission-form/?from=4 further details on the investigation: before the market opened on february 28, 2022, viatris unexpectedly announced the company had entered into an agreement to sell its biosimilars business to biocon biologics limited, which was anticipated to close in the second half of 2022. additionally, viatris announced that it was seeking to divest additional business assets and undertaking a significant global reshaping of its business, which would focus on developing products in three core therapeutic areas: ophthalmology, gastrointestinal and dermatology.
VTRS Ratings Summary
VTRS Quant Ranking